Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M868Revenue $M14.2Net Margin (%)-787.6Z-Score7.7
Enterprise Value $M644EPS $-3.3Operating Margin %-635.0F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-787.6Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %-9.1Quick Ratio6.6Cash flow > EarningsY
Price/Sales47.65-y EBITDA Growth Rate %25.2Current Ratio6.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-38.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-45.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M40.7ROI % (ttm)-300.9Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 21.34-16%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 21.34-28%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 21.34-44%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 21.34-26%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 21.34-20%Add 184.13%226,429
SRPTJean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6
($6.06)
$ 21.34252%Sold Out0
SRPTJean-Marie Eveillard 2011-12-31 Reduce$3.24 - $6.54
($5.04)
$ 21.34323%Reduce -83.33%50,000
SRPTJean-Marie Eveillard 2011-09-30 Add$6.3 - $9.9
($7.92)
$ 21.34169%Add 50%300,000
SRPTJean-Marie Eveillard 2011-06-30 Buy $8.1 - $11.22
($9.66)
$ 21.34121%New holding, 200000 sh.200,000
SRPTGeorge Soros 2006-03-31 Buy 0.08%$24.54 - $50.45
($41.39)
$ 21.34-48%New holding, 308100 sh.308,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SRPT George Soros 2014-03-3125,0000.060.01-89.27%
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.9552.97view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.5669.9view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-42.39view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-38.98view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-34.7view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.1-31.38view
Price Ben GilDirector 2013-08-19Buy500$31.18-31.56view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-44.57view
CHASE ANTHONY RDirector 2012-11-28Sell10,000$29.46-27.56view
CHASE ANTHONY RDirector 2012-11-14Sell10,000$25.7-16.96view

Press Releases about SRPT :

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Insiders Are Buying Fate Therapeutics Oct 09 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Feb 16 2013 


More From Other Websites
Coverage initiated on Sarepta Therapeutics by Oppenheimer Aug 01 2014
CEO Reasserts Control Over Biotech Developer of Muscular Dystrophy Drug Aug 01 2014
Nasdaq stocks posting largest percentage decreases Jul 31 2014
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 31 2014
5:12 pm Sarepta Therapeutics announces appointment of John Hodgman as interim chairman Jul 31 2014
Sarepta Therapeutics Announces Appointment of John Hodgman As Interim Chairman Jul 31 2014
Sarepta Therapeutics to Announce Second Quarter 2014 Financial Results and Corporate Update on... Jul 31 2014
Sarepta Therapeutics to Present Company Overview at Canaccord Annual Growth Conference Jul 31 2014
Sarepta Therapeutics to Present Company Overview at Canaccord Annual Growth Conference Jul 31 2014
Sarepta Therapeutics to Announce Second Quarter 2014 Financial Results and Corporate Update on... Jul 31 2014
Sarepta Therapeutics (SRPT) Soars: Stock Rises 12.8% Jul 31 2014
Sarepta Up 12% As FDA Is 'Actively Engaged' On Drug Application Jul 30 2014
Here's Why Aegerion and Sarepta Trade Higher Wednesday Jul 30 2014
[$$] Sarepta CEO Sheds Some Sway Over Management Jul 29 2014
Stop Squabbling, Mom Tells Troubled Biotech: 'Just Get My Kid the Drug' Jul 28 2014
[$$] Chief Scientist Out at Sarepta Therapeutics Jul 25 2014
Sarepta fired CSO not involved in eteplirsen, The Street reports Jul 24 2014
The Story Behind Sarepta's Firing of its Top Scientist Jul 24 2014
Sarepta terminates Chief Scientific Officer Arthur Krieg Jul 24 2014
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jul 24 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide